Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.

In the patients who had received nivolumab, the median plasma concentration was also higher in those who developed severe hepatotoxicity ( n = 4) compared to those who did not ( n = 6) (14.5 versus 7.2 μg/mL), although this did not reach statistical significance due to the small sample size ( p = 0.61, Mann–Whitney U Test).

also in 111,027 other papers